Form 4: Clorox Director Matthew Shattock Increases Equity Stake

Sentiment:

Director Equity Acquisition


Director Matthew J. Shattock acquired 506.61 deferred stock units in lieu of quarterly director fees, increasing his total holdings.

Summary

  • Director Matthew J. Shattock acquired 506.6101 deferred stock units on March 31, 2026, in lieu of quarterly director fees.
  • An additional 191.2909 deferred stock units were acquired on February 13, 2026, through dividend reinvestment.
  • The total beneficial ownership of deferred stock units following these transactions is 20,126.2673.
  • These units are 1-for-1 and will be settled in common stock upon the director's retirement or termination of service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine director compensation and continued alignment with shareholder interests.

Positives

  • Director demonstrates alignment with shareholder interests by opting to receive compensation in equity rather than cash.
  • Increased total beneficial ownership of 20,126.2673 units reflects long-term commitment to the company.

Negatives

  • None identified.

Risks

  • Value of deferred stock units is tied directly to the future performance of Clorox common stock.

Future Outlook

The deferred stock units will be settled 100% in Clorox common stock upon the director's retirement or termination of service.

Management Comments

  • The transactions reflect standard director compensation practices under the Independent Directors' Deferred Compensation Plan.

Industry Context

StockSavvy.ai notes that director equity accumulation is a standard corporate governance practice, signaling confidence in long-term company stability within the consumer staples sector.

Comparison to Industry Standards

  • The use of deferred stock units for director compensation is consistent with governance practices at major consumer goods companies like Procter & Gamble and Colgate-Palmolive.

Stakeholder Impact

  • Shareholders benefit from director alignment through equity-based compensation.

Next Steps

  • Settlement of deferred stock units into common stock upon the director's future retirement or termination of service.

Key Dates

DateDescription
02/13/2026Acquisition of deferred stock units via dividend reinvestment.
03/31/2026Acquisition of deferred stock units in lieu of quarterly director fees.
04/02/2026Filing date of the Form 4.

Keywords

Clorox, CLX, Director Compensation, Insider Ownership, Deferred Stock Units, Equity

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.